Human CellExp™ SARS-CoV-2 S1 (K417N), Recombinant

Biomolecule/Target: N/A

Synonyms: S1 Protein, Spike glycoprotein subunit1, S glycoprotein subunit1, SARS-CoV-2 S1 Protein

Alternates names: S1 Protein, Spike glycoprotein subunit1, S glycoprotein subunit1, SARS-CoV-2 S1 Protein

Taglines: A key protein in allowing viral entry into host cells

Taglines: USA

Country of Animal Origin: USA

NCBI Gene ID #.: 43740568

NCBI Gene Symbol: N/A

Gene Source: SARS-CoV-2

Accession #: P0DTC2

Recombinant: True

Source: HEK 293 cells

Purity by SDS-PAGE #: > 95% by SDS-PAGE

Assay: N/A

Purity: N/A

Assay #2: N/A

Endotoxin Level: N/A

Activity (Specifications/test method): N/A

Biological activity: N/A

Results: N/A

Binding Capacity: N/A

Unit Definition: N/A

Molecular Weight: ~120 kDa (8xHis tag at the C-terminus)

Concentration: N/A

Appearance: Lyophilized protein

Physical form description: Lyophilized powder

Reconstitution Instructions: Centrifuge the vial prior to opening. Reconstitute in sterile PBS (pH 7.4). Do not vortex

Background Information: SARS-CoV-2, the causative virus of COVID-19, uses the viral Spike (S) protein for host cell attachment and entry. The virus uses multiple host targets including the human protease Furin, Angiotensin converting enzyme 2 (ACE2), Neuropilin-1 (NRP1) and the transmembrane protease serine 2 (TMPRSS2) for host cell entry. The S protein has two domains S1 and S2, where S1 facilitates initial binding to the receptor and the S2 domain drives the membrane fusion and eventual entry of the virus. The S glycoprotein serves as an important target for monoclonal antibodies, entry inhibitors, and vaccines. Within the S1 protein, the conserved receptor-binding domain (RBD) binds with a high affinity for ACE2. Recently, fast-spreading variants were identified in the UK, South Africa, and Brazil. One of those variants of SARS-CoV-2 contains the K417N mutation, which is a lysine (K) to asparagine (N) substitution at position 417 in the RBD. Epidemiologist estimated that the new variant is roughly 50% more transmissible as compared to other dominant lineages based on the rate it spreads. According to the CDC, they also claim a moderate impact on neutralization by monoclonal antibody therapeutics and convalescent/post-vaccination sera.

Amino acid sequence: Val 16 - Arg 685

Handling: Centrifuge the vial prior to opening.

Usage: For Research Use Only! Not to be used in humans